CA
NZ
UK
AU
IND
US
• The company's ProSense cryoablation system continues to expand into new tumor indications.
• KARD shares were roughly flat intraday, up 0.13% to $23.88, stabilizing after a 7.92% decline in the prior session.
• The company appointed a globally recognized diabetic foot care expert as Study Chair for its Phase 2a Nu-3 trial.
• Unicycive Therapeutics has drawn heightened market attention after a sharp share-price decline that placed it among notable biotech decliners.
• Universe Pharmaceuticals has drawn heightened market attention after a notable share-price slide that placed it among the day's pharmaceutical decliners.
• Virax Biolabs has drawn renewed market attention after a share-price slide that reflects fresh pressure on small-capitalisation biotech names.
• Orchestra BioMed has drawn heightened market attention following share-price weakness that has placed the clinical-stage biotech under closer investor examination.
• Protara Therapeutics has drawn heightened market attention after a share-price slide that lines up with a fresh check on biotech sentiment.
• Fiscal 2026 net sales were $190.5 million, down 14.3% year over year, or 5.4% when adjusted for prior-year order timing.
• AC Immune has drawn increased market attention after a share-price decline that coincides with wavering sentiment across the biotech space.
Please wait processing your request...